A Multicenter Retrospective Review of Management Strategies in Small Bowel Obstruction

March 20, 2026 updated by: Methodist Health System
The objective of the study is to review performance of water soluble contrast study in patients admitted with Small Bowel Obstruction(SBO), will improve quality and safety, and decrease length of stay and morbidity.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

Performance of contrast study has been a part of the protocols at multiple institutions of the southwestern surgical congress. Plan to perform a retrospective review of management protocols at these institutions. Wish to know whether the implementation of a standardized, protocol-driven pattern of practice involving the performance of water soluble contrast study in patients admitted with SBO, will improve quality and safety, and decrease length of stay and morbidity.

The objective of the study is to review performance of water soluble contrast study in patients admitted with SBO, will improve quality and safety, and decrease length of stay and morbidity.

Performance of contrast study has been a part of the protocols at multiple institutions of the southwestern surgical congress.

Hypothesize that implementation of a standardized, protocol-driven pattern of practice involving the performance of water soluble contrast study in patients admitted with SBO, will improve quality and safety, and decrease length of stay and morbidity.

Study Type

Observational

Enrollment (Actual)

504

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • United States
    • Texas
      • Dallas, Texas, United States, 75201
        • Methodist Dallas Medical Center

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

Previous studies found on an average 3.9 to 9.4% patient suffer from SBO. The disease incidence varies depending on the cause of obstruction. Assuming that 3.9% of the patients will be affected by SBO, the study would require a sample size of 504 for estimating the expected proportion with 3% absolute precision and 95% confidence.

Description

Inclusion Criteria:

  • • Adults aged 18-89 years of age

    • Patients presenting with SBO

Exclusion Criteria:

  • • Prisoners

    • Pregnant women

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Morbidity and length of stay
Time Frame: 1 year
Morbidity and length of stay
1 year

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Patient demographics
Time Frame: 1 year
number of patients (age, sex, weight, height)
1 year
admit date
Time Frame: 1 year
Number of patients admitting to the hospital
1 year
discharge date
Time Frame: 1 year
number of patients discharging
1 year
admission service
Time Frame: 1 year
Number of services related to admissions
1 year
Aspirin(ASA )class
Time Frame: 1 year
number of aspirin class
1 year
comorbidities
Time Frame: 1 year
number of comorbidities associated
1 year
surgical history
Time Frame: 1 year
number of surgeries in the past
1 year
labs
Time Frame: 1 year
number of labs done
1 year
time of contrast given
Time Frame: 1 year
rate of Contrast given
1 year

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Methodist Health System

Investigators

  • Principal Investigator: Michael Truitt, MD, The Methodist Hospital Research Institute

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

July 30, 2018

Primary Completion (Actual)

December 31, 2019

Study Completion (Actual)

December 31, 2019

Study Registration Dates

First Submitted

October 18, 2023

First Submitted That Met QC Criteria

January 16, 2024

First Posted (Actual)

January 25, 2024

Study Record Updates

Last Update Posted (Actual)

March 24, 2026

Last Update Submitted That Met QC Criteria

March 20, 2026

Last Verified

January 1, 2024

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 046.GME.2018.D

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on SBO - Small Bowel Obstruction

Clinical Trials on review performance of water soluble contrast

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Czech Republic

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe